Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Phone617-301-9400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$37.63 million
Profitability
Miscellaneous
Employees177
Next Earnings DateN/A
OptionableNot Optionable
Quanterix (NASDAQ:QTRX) Frequently Asked Questions
What is Quanterix's stock symbol?
Quanterix trades on the NASDAQ under the ticker symbol "QTRX."
How were Quanterix's earnings last quarter?
Quanterix Corp (NASDAQ:QTRX) announced its earnings results on Monday, March, 18th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.17. The business earned $10.88 million during the quarter, compared to analyst estimates of $9.69 million. Quanterix had a negative return on equity of 76.62% and a negative net margin of 79.48%. View Quanterix's Earnings History.
What price target have analysts set for QTRX?
1 brokerages have issued 12 month target prices for Quanterix's shares. Their predictions range from $32.00 to $32.00. On average, they anticipate Quanterix's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 45.1% from the stock's current price. View Analyst Price Targets for Quanterix.
What is the consensus analysts' recommendation for Quanterix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix.
What are Wall Street analysts saying about Quanterix stock?
Here are some recent quotes from research analysts about Quanterix stock:
- 1. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (5/15/2019)
- 2. Canaccord Genuity analysts commented, "We recommend investors own QTRX as it targets growth across four phases: (1) expansion in life sciences research, and likely expansion to (2) companion diagnostics; (3) point-of-care in vitro diagnostics, and, longer term, (4) precision health and wellness screening. We reiterate our BUY rating and raise our PT to $32 (from $29). Q1 beat. Q1 revs of $12.3M (+64% Y/Y) beat our $10.5ME (+39%)/ Street’s $10.2M, driven by triple-digit (+124%) growth in consumables revs and +70% growth in instruments revs, both well above our +58% and +20% estimates. Product revs of $9.5M (+101% Y/Y) beat our $6.7M, while service revs of $2.8M (+11% Y/Y) were below our $3.7M (+35%), as QTRX allocated its time and resources more toward driving volume growth in high-margin consumables." (5/10/2019)
Has Quanterix been receiving favorable news coverage?
Headlines about QTRX stock have been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Quanterix earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Quanterix's key competitors?
Some companies that are related to Quanterix include Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), Arrayit (ARYC), Precipio (PRPO), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO) and PositiveID (PSID).
What other stocks do shareholders of Quanterix own?
Who are Quanterix's key executives?
Quanterix's management team includes the folowing people:
- Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)
- Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)
- Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)
- Mr. Amol Chaubal, Chief Financial Officer (Age 43)
- Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 60)
When did Quanterix IPO?
(QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.
Who are Quanterix's major shareholders?
Quanterix's stock is owned by a number of of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (4.37%), FMR LLC (3.44%), BlackRock Inc. (3.00%), Royce & Associates LP (2.87%), Park West Asset Management LLC (0.62%) and Geode Capital Management LLC (0.56%). Company insiders that own Quanterix stock include David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John M Connolly, Joseph Driscoll, Mark T Roskey and Venture Fund Viii Overage Arch. View Institutional Ownership Trends for Quanterix.
Which major investors are selling Quanterix stock?
QTRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Royce & Associates LP, Park West Asset Management LLC, PNC Financial Services Group Inc. and Acadian Asset Management LLC. Company insiders that have sold Quanterix company stock in the last year include David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, Joseph Driscoll and Mark T Roskey. View Insider Buying and Selling for Quanterix.
Which major investors are buying Quanterix stock?
QTRX stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, EAM Global Investors LLC, Geode Capital Management LLC, SEI Investments Co, Wells Fargo & Company MN, Spark Investment Management LLC, Macquarie Group Ltd. and BlackRock Inc.. Company insiders that have bought Quanterix stock in the last two years include David R Walt, E Kevin Hrusovsky, John M Connolly and Venture Fund Viii Overage Arch. View Insider Buying and Selling for Quanterix.
How do I buy shares of Quanterix?
Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quanterix's stock price today?
One share of QTRX stock can currently be purchased for approximately $22.06.
How big of a company is Quanterix?
Quanterix has a market capitalization of $498.56 million and generates $37.63 million in revenue each year. The company earns $-31,540,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Quanterix employs 177 workers across the globe.
What is Quanterix's official website?
How can I contact Quanterix?
Quanterix's mailing address is 113 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-301-9400.
MarketBeat Community Rating for Quanterix (NASDAQ QTRX)
MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
